Glenmark Pharmaceuticals

GLENMARK NSE Healthcare Pharmaceuticals
Nifty 200 Nifty 500 Midcap 100 Midcap 150 LargeMid 250 F&O
₹2,419.20
+0.17%
Delayed · cached 15 min
Fair Value Analysis →

Price Chart

Price50-day avg200-day avg

How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.

Strengths

  • Low debt: debt-to-equity of 0.06.
  • Comfortable interest cover: operating profit covers interest about 21.9 times.
  • Return on equity is healthy at 23.6%.
  • Return on capital employed is healthy at 39.8%.
  • Net profit margin is 8%.
  • Profit has compounded about 19% a year over five years.
  • Pays a dividend (yield about 0.21%).
  • Has paid a dividend in 4 of the last 5 years.
  • Promoters hold a sizeable stake (46.65%).

!Watch-points

No notable watch-points flagged by the automated checks.

These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.

Forensic Checks

Altman Z-ScoreSafe zone
4.42

In Altman’s original study, companies in this range showed a low incidence of financial distress.

Computed without the working-capital term (current-asset split not available for this stock).

Piotroski F-ScoreStrong
7 / 7

The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.

Based on 7 of the 9 signals — the rest need data not available for this stock.

These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.

Key Ratios

Market Cap₹ 68,276 Cr
Current Price₹ 2,419.20
High / Low₹ 2,537.60 / 1,792.60
Stock P/E37.942284
Book Value₹ 372.00
Dividend Yield0.1%
ROCE39.80%
ROE23.60%
Face Value₹ 1.00
Debt to Equity0.06
PEG Ratio0.36
EV / EBITDA13.48
Industry PE35.25
P/B Ratio6.494932
EPS₹ 48.26
Debt₹ 594 Cr
PAT Margin8.02%
Cash PAT₹ 1,935 Cr
ICR21.88
Promoter Holding46.65%
FII Holding20.89%
DII Holding18.60%
Public Holding13.81%

Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).

Compounded Sales Growth
10 Years 8.00%
5 Years 9.00%
3 Years 14.00%
TTM 33.00%
Compounded Profit Growth
10 Years 12.00%
5 Years 19.00%
3 Years 61.00%
TTM 134.00%
Stock Price CAGR
10 Years 11.00%
5 Years 35.00%
3 Years 45.00%
1 Year 19.00%
Return on Equity
10 Years 7.00%
5 Years 2.00%
3 Years -3.00%
Last Year 24.00%
Educational data only. Not a recommendation to buy, sell or hold any security.